Lineage, Inc. Common Stock (LINE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Lineage, Inc. Common Stock stock (LINE) is currently trading at $34.89. Lineage, Inc. Common Stock PS ratio (Price-to-Sales) is 1.65. Analyst consensus price target for LINE is $41.95. WallStSmart rates LINE as Sell.
- LINE PE ratio analysis and historical PE chart
- LINE PS ratio (Price-to-Sales) history and trend
- LINE intrinsic value — DCF, Graham Number, EPV models
- LINE stock price prediction 2025 2026 2027 2028 2029 2030
- LINE fair value vs current price
- LINE insider transactions and insider buying
- Is LINE undervalued or overvalued?
- Lineage, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- LINE Piotroski F-Score and Altman Z-Score
- LINE analyst price target and Smart Rating
Lineage, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Lineage, Inc. Common Stock (LINE) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Lineage, Inc. Common Stock (LINE) Key Strengths (3)
Trading below book value, meaning the market prices it less than net assets
Paying $1.65 for every $1 of annual revenue
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Lineage, Inc. Common Stock (LINE) Areas to Watch (5)
Company is destroying shareholder value
Revenue declining -0.20%, a shrinking business
Company is losing money with a negative profit margin
Very thin margins with limited operational efficiency
Moderate institutional interest at 33.45%
Supporting Valuation Data
Lineage, Inc. Common Stock (LINE) Detailed Analysis Report
Overall Assessment
This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 8.3/10) while 5 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Price/Sales, Market Cap. Valuation metrics including Price/Sales (1.65), Price/Book (0.97) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Profit Margin. Growth concerns include Revenue Growth at -0.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -1.19%, Operating Margin at 5.17%, Profit Margin at -1.87%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1.19% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -0.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LINE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LINE's Price-to-Sales ratio of 1.65x trades 22% below its historical average of 2.11x (19th percentile). The current valuation is 54% below its historical high of 3.59x set in Aug 2024, and 10% above its historical low of 1.5x in Dec 2025. Over the past 12 months, the PS ratio has compressed from ~2.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Lineage, Inc. Common Stock (LINE) · REAL ESTATE › REIT - INDUSTRIAL
The Big Picture
Lineage, Inc. Common Stock is in a turnaround phase, with management focused on restoring profitability. Revenue reached 5.4B with 20% decline year-over-year. The company is currently unprofitable, posting a -187.0% profit margin.
Key Findings
Generating 78M in free cash flow and 316M in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 20% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -187.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Dividend sustainability with a current yield of 6.0%. Watch payout ratio and free cash flow coverage.
Sector dynamics: monitor REIT - INDUSTRIAL industry trends, competitive moves, and regulatory changes that could impact Lineage, Inc. Common Stock.
Bottom Line
Lineage, Inc. Common Stock is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Lineage, Inc. Common Stock(LINE)
NASDAQ
REAL ESTATE
REIT - INDUSTRIAL
USA
Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company at the forefront of regenerative medicine, specializing in the development of advanced cell therapy solutions aimed at treating severe diseases such as eye disorders, spinal cord injuries, and cancer. Leveraging proprietary technologies and a strong commitment to strategic partnerships, the company is dedicated to revolutionizing patient care with its novel therapeutic approaches. As Lineage continues to enhance its diverse product pipeline and accelerate clinical research initiatives, it represents a compelling opportunity for institutional investors looking to support transformative advancements in healthcare.